Ici 200880 | CAS#105080-50-0 | neutrophil elastase inhibitor

MedKoo Cat#: 597827 | Name: Ici 200880

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ici 200880 is a synthetic peptide inhibitor of human neutrophil elastase.

Chemical Structure

Ici 200880

CAS#105080-50-0

Theoretical Analysis

MedKoo Cat#: 597827

Name: Ici 200880

CAS#: 105080-50-0

Chemical Formula: C30H34ClF3N4O7S

Exact Mass: 686.1789

Molecular Weight: 687.12

Elemental Analysis: C, 52.44; H, 4.99; Cl, 5.16; F, 8.29; N, 8.15; O, 16.30; S, 4.67

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Ici 200880; Ici-200880; Ici200880; Ici 200,880; Ic-200,880; Ici200,880;

IUPAC/Chemical Name

N1-((4-chlorophenyl)sulfonyl)-N4-((2S)-3-methyl-1-oxo-1-((2S)-2-((1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl)carbamoyl)pyrrolidin-1-yl)butan-2-yl)terephthalamide

InChi Key

YGPYJEFIYYPEEE-OTKIHZFJSA-N

InChi Code

InChI=1S/C30H34ClF3N4O7S/c1-16(2)23(25(39)30(32,33)34)35-28(42)22-6-5-15-38(22)29(43)24(17(3)4)36-26(40)18-7-9-19(10-8-18)27(41)37-46(44,45)21-13-11-20(31)12-14-21/h7-14,16-17,22-24H,5-6,15H2,1-4H3,(H,35,42)(H,36,40)(H,37,41)/t22-,23?,24-/m0/s1

SMILES Code

O=C(NC(C(C)C)C(C(F)(F)F)=O)[C@H]1N(C([C@H](C(C)C)NC(C2=CC=C(C(NS(=O)(C3=CC=C(Cl)C=C3)=O)=O)C=C2)=O)=O)CCC1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 687.12 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Williams JC, Stein RL, Giles RE, Krell RD. Biochemistry and pharmacology of ICI 200,880, a synthetic peptide inhibitor of human neutrophil elastase. Ann N Y Acad Sci. 1991;624:230-43. PubMed PMID: 2064224. 2: Davis PC, Wildonger RA, Veale HS. A specific radioimmunoassay for the measurement of ICI 200,880, an elastase inhibitor, in human serum. J Pharm Biomed Anal. 1993 Jul;11(7):549-56. PubMed PMID: 8399528. 3: Williams JC, Falcone RC, Knee C, Stein RL, Strimpler AM, Reaves B, Giles RE, Krell RD. Biologic characterization of ICI 200,880 and ICI 200,355, novel inhibitors of human neutrophil elastase. Am Rev Respir Dis. 1991 Oct;144(4):875-83. PubMed PMID: 1928965. 4: Mehta JL, Nichols WW, Nicolini FA, Hendricks J, Donnelly WH, Saldeen TG. Neutrophil elastase inhibitor ICI 200,880 protects against attenuation of coronary flow reserve and myocardial dysfunction following temporary coronary artery occlusion in the dog. Cardiovasc Res. 1994 Jul;28(7):947-56. PubMed PMID: 7954605. 5: Tiefenbacher CP, Ebert M, Niroomand F, Batkai S, Tillmanns H, Zimmermann R, Kübler W. Inhibition of elastase improves myocardial function after repetitive ischaemia and myocardial infarction in the rat heart. Pflugers Arch. 1997 Mar;433(5):563-70. PubMed PMID: 9049140. 6: Turino GM, Davies P, Dunlap R, Krell RD, Maycock AL, Rennard S, Stockley RA. Selection of a therapeutic agent for the treatment of chronic obstructive pulmonary disease in smokers. Ann N Y Acad Sci. 1991 Dec 31;624 Suppl:23-30. PubMed PMID: 1686162. 7: Pacholok SG, Davies P, Dorn C, Finke P, Hanlon WA, Mumford RA, Humes JL. Formation of polymorphonuclear leukocyte elastase: alpha 1 proteinase inhibitor complex and A alpha (1-21) fibrinopeptide in human blood stimulated with the calcium ionophore A23187. A model to characterize inhibitors of polymorphonuclear leukocyte elastase. Biochem Pharmacol. 1995 May 17;49(10):1513-20. PubMed PMID: 7763294. 8: Bernstein PR, Gomes BC, Kosmider BJ, Vacek EP, Williams JC. Nonpeptidic inhibitors of human leukocyte elastase. 6. Design of a potent, intratracheally active, pyridone-based trifluoromethyl ketone. J Med Chem. 1995 Jan 6;38(1):212-5. PubMed PMID: 7837235. 9: Nicolini FA, Mehta JL, Nichols WW, Donnelly WH, Luostarinen R, Saldeen TG. Leukocyte elastase inhibition and t-PA-induced coronary artery thrombolysis in dogs: beneficial effects on myocardial histology. Am Heart J. 1991 Nov;122(5):1245-51. PubMed PMID: 1950986. 10: Brown FJ, Andisik DW, Bernstein PR, Bryant CB, Ceccarelli C, Damewood JR Jr, Edwards PD, Earley RA, Feeney S, Green RC, et al. Design of orally active, non-peptidic inhibitors of human leukocyte elastase. J Med Chem. 1994 Apr 29;37(9):1259-61. PubMed PMID: 8176703.